Drug Profile


Alternative Names: AGC; Analgecine

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Vanway
  • Class Analgesics; Anti-ischaemics; Antiallergics; Biological factors; Hypnosedatives; Neuroprotectants
  • Mechanism of Action Bradykinin inhibitors; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Neuralgia
  • Phase III Neuropathic pain

Most Recent Events

  • 01 Jul 2014 Vanway completes a phase III trial in Back pain in China (NCT02168010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top